Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 113,717,168
  • Shares Outstanding, K 2,035,753
  • Annual Sales, $ 48,300 M
  • Annual Income, $ -8,948 M
  • EBIT $ 12,215 M
  • EBITDA $ 21,815 M
  • 60-Month Beta 0.29
  • Price/Sales 2.37
  • Price/Cash Flow 9.50
  • Price/Book 6.12

Options Overview Details

View History
  • Implied Volatility 29.72% (-0.14%)
  • Historical Volatility 27.48%
  • IV Percentile 43%
  • IV Rank 26.15%
  • IV High 55.70% on 04/10/25
  • IV Low 20.52% on 12/31/25
  • Expected Move (DTE 4) 1.42 (2.54%)
  • Put/Call Vol Ratio 1.05
  • Today's Volume 29,154
  • Volume Avg (30-Day) 64,896
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 728,534
  • Open Int (30-Day) 752,021
  • Expected Range 54.44 to 57.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.65
  • Number of Estimates 9
  • High Estimate 1.74
  • Low Estimate 1.57
  • Prior Year 1.67
  • Growth Rate Est. (year over year) -1.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.33 +10.99%
on 12/10/25
56.97 -1.95%
on 01/08/26
+5.21 (+10.29%)
since 12/09/25
3-Month
42.52 +31.37%
on 10/29/25
56.97 -1.95%
on 01/08/26
+11.18 (+25.02%)
since 10/09/25
52-Week
42.52 +31.37%
on 10/29/25
63.33 -11.80%
on 03/11/25
-0.95 (-1.67%)
since 01/08/25

Most Recent Stories

More News
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

SCOUT-HCM demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpoints The overall safety results...

BMY : 55.86 (-0.07%)
Stocks Settle Mostly Lower as Early Rally Fades

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -0.34%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.94%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.06%. March E-mini...

MSTR : 157.33 (-5.77%)
B : 47.81 (+0.78%)
HL : 22.45 (+6.85%)
CDE : 20.40 (+3.98%)
JPM : 329.19 (-0.18%)
TXN : 190.31 (+0.99%)
$IUXX : 25,766.26 (+1.02%)
AMGN : 326.10 (-1.21%)
ZNH26 : 112-015 (-0.15%)
ESH26 : 6,961.50 (-0.62%)
GLUE : 24.28 (-4.07%)
STX : 304.01 (+6.87%)
Worried About a K-Shaped Economy? Buy This Top Dividend ETF for 2026.

SCHD looks well-positioned to outperform significantly if the economy turns south in 2026.

LMT : 542.92 (+4.72%)
KO : 70.51 (+1.64%)
SCHD : 28.55 (+0.46%)
PEP : 139.91 (+0.39%)
ABBV : 220.08 (-1.81%)
AMGN : 326.10 (-1.21%)
PFE : 25.48 (+0.75%)
BMY : 55.86 (-0.07%)
Should You Chase the Rally in Alumis Stock Today?

Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.

JNJ : 204.39 (-0.66%)
ALMS : 19.56 (+7.59%)
BMY : 55.86 (-0.07%)
Stocks Hover Near Record Highs on Mixed US Economic News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.36%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.34%. March E-mini S&P futures (ESH26...

MSTR : 157.33 (-5.77%)
AMAT : 301.18 (+6.94%)
B : 47.81 (+0.78%)
HL : 22.45 (+6.85%)
CDE : 20.40 (+3.98%)
JPM : 329.19 (-0.18%)
TXN : 190.31 (+0.99%)
$IUXX : 25,766.26 (+1.02%)
AMGN : 326.10 (-1.21%)
ZNH26 : 112-015 (-0.15%)
ESH26 : 6,961.50 (-0.62%)
GLUE : 24.28 (-4.07%)
Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference

Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 44 th Annual Healthcare Conference on Monday, January 12, 2026. The...

BMY : 55.86 (-0.07%)
2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky

2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky

LNTH : 67.56 (-0.43%)
DXCM : 67.40 (-1.51%)
BMY : 55.86 (-0.07%)
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology

Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from...

AZN : 94.65 (+0.68%)
PPCB : 0.4622 (-3.79%)
RHHBY : 53.4000 (+1.19%)
BMY : 55.86 (-0.07%)
The Healthcare Sector is Gaining Momentum. Watch This Stock Chart for a Reversal Setup.

Our top chart strategist is tracking a 3-candle drop pattern on AHR.

XLV : 157.31 (-0.51%)
$SPX : 6,966.28 (+0.65%)
AHR : 47.28 (-0.13%)
BMY : 55.86 (-0.07%)
Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

Eliquis® (apixaban), the Nation’s #1 Prescribed Oral Blood Thinner, Soon Available for Free to Medicaid Program Agreement Provides Tariff Relief for...

BMY : 55.86 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 56.97
2nd Resistance Point 56.65
1st Resistance Point 56.26
Last Price 55.86
1st Support Level 55.54
2nd Support Level 55.22
3rd Support Level 54.83

See More

52-Week High 63.33
Last Price 55.86
Fibonacci 61.8% 55.38
Fibonacci 50% 52.93
Fibonacci 38.2% 50.47
52-Week Low 42.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar